HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tangri, S. Articles by Sette, A. Search for Related Content PubMed PubMed Citation Articles by Tangri, S. Articles by Sette, A.

Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity

Shabnam Tangri^*, Bianca R. Mothé^*,, Julie Eisenbraun^*, John Sidney^*,, Scott Southwood^*, Kristen Briggs^*, John Zinckgraf^*, Pamuk Bilsel^*, Mark Newman^*, Robert Chesnut^*, Cynthia LiCalsi^* and Alessandro Sette^1,*,

^* Epimmune, San Diego, CA 92121; California State University, San Marcos, CA 95096; and La Jolla Institute for Allergy and Immunology, San Diego, CA 92121

Chronic administration of protein therapeutics may elicit unacceptable immune responses to the specific protein. Our hypothesis is that the immunogenicity of protein drugs can be ascribed to a few immunodominant helper T lymphocyte (HTL) epitopes, and that reducing the MHC binding affinity of these HTL epitopes contained within these proteins can generate drugs with lower immunogenicity. To test this hypothesis, we studied the protein therapeutic erythropoietin (Epo). Two regions within Epo, designated Epo 91–120 and Epo 126–155, contained HTL epitopes that were recognized by individuals with numerous HLA-DR types, a property common to immunodominant HTL epitopes. We then engineered analog epitopes with reduced HLA binding affinity. These analog epitopes were associated with reduced in vitro immunogenicity. Two modified forms of Epo containing these substitutions were shown to be bioactive and nonimmunogenic in vitro. These findings support our hypothesis and demonstrate that immunogenicity of protein drugs can be reduced in a systematic and predictable manner.

This article has been cited by other articles:

				B. R. Mothe, B. S. Stewart, C. Oseroff, H.-H. Bui, S. Stogiera, Z. Garcia, C. Dow, M. P. Rodriguez-Carreno, M. Kotturi, V. Pasquetto, et al. Chronic Lymphocytic Choriomeningitis Virus Infection Actively Down-Regulates CD4+ T Cell Responses Directed against a Broad Range of Epitopes J. Immunol., July 15, 2007; 179(2): 1058 - 1067. [Abstract] [Full Text] [PDF]

				M. Onda, S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al. Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients J. Immunol., December 15, 2006; 177(12): 8822 - 8834. [Abstract] [Full Text] [PDF]

				C. Lico, F. Capuano, G. Renzone, M. Donini, C. Marusic, A. Scaloni, E. Benvenuto, and S. Baschieri Peptide display on Potato virus X: molecular features of the coat protein-fused peptide affecting cell-to-cell and phloem movement of chimeric virus particles. J. Gen. Virol., October 1, 2006; 87(Pt 10): 3103 - 3112. [Abstract] [Full Text] [PDF]

				B. Janjic, P. Andrade, X.-F. Wang, J. Fourcade, C. Almunia, P. Kudela, A. Brufsky, S. Jacobs, D. Friedland, R. Stoller, et al. Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers J. Immunol., August 15, 2006; 177(4): 2717 - 2727. [Abstract] [Full Text] [PDF]

				W. M. Cohen, S. Pouvelle-Moratille, X.-F. Wang, S. Farci, G. Munier, D. Charron, A. Menez, M. Busson, and B. Maillere Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule J. Immunol., May 1, 2006; 176(9): 5401 - 5408. [Abstract] [Full Text] [PDF]